305 related articles for article (PubMed ID: 28941219)
1. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
Mariette X; Chen C; Biswas P; Kwok K; Boy MG
Arthritis Care Res (Hoboken); 2018 May; 70(5):685-694. PubMed ID: 28941219
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
6. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
[TBL] [Abstract][Full Text] [Related]
9. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
[TBL] [Abstract][Full Text] [Related]
10. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
[TBL] [Abstract][Full Text] [Related]
14. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Curtis JR; Lee EB; Martin G; Mariette X; Terry KK; Chen Y; Geier J; Andrews J; Kaur M; Fan H; Nduaka CI
Clin Exp Rheumatol; 2017; 35(4):614-622. PubMed ID: 28240592
[TBL] [Abstract][Full Text] [Related]
15. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Charles-Schoeman C; Burmester G; Nash P; Zerbini CA; Soma K; Kwok K; Hendrikx T; Bananis E; Fleischmann R
Ann Rheum Dis; 2016 Jul; 75(7):1293-301. PubMed ID: 26275429
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Winthrop KL; Park SH; Gul A; Cardiel MH; Gomez-Reino JJ; Tanaka Y; Kwok K; Lukic T; Mortensen E; Ponce de Leon D; Riese R; Valdez H
Ann Rheum Dis; 2016 Jun; 75(6):1133-8. PubMed ID: 26318385
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Wang L; Chen C; Kwok K; Biswas P; Shapiro A; Madsen A; Wollenhaupt J
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33127856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
